Hennion & Walsh Asset Management Inc. Grows Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 44.9% in the first quarter, HoldingsChannel reports. The fund owned 109,820 shares of the company’s stock after acquiring an additional 34,040 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Viridian Therapeutics were worth $1,923,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Viridian Therapeutics by 122.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock valued at $182,000 after buying an additional 4,610 shares in the last quarter. Arizona State Retirement System bought a new stake in Viridian Therapeutics during the 4th quarter valued at about $208,000. Dark Forest Capital Management LP purchased a new position in Viridian Therapeutics in the third quarter worth about $264,000. New York State Common Retirement Fund raised its holdings in Viridian Therapeutics by 9.7% in the fourth quarter. New York State Common Retirement Fund now owns 17,495 shares of the company’s stock worth $378,000 after buying an additional 1,545 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Viridian Therapeutics in the fourth quarter worth approximately $424,000.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on VRDN shares. LADENBURG THALM/SH SH downgraded shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $30.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, June 11th. Wolfe Research initiated coverage on Viridian Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $29.00 price objective on the stock. B. Riley lowered Viridian Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $25.00 to $20.00 in a research report on Thursday, May 9th. Finally, HC Wainwright lowered their target price on shares of Viridian Therapeutics from $37.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $13.01 on Friday. The company has a 50-day moving average price of $13.12 and a 200-day moving average price of $17.03. Viridian Therapeutics, Inc. has a 52 week low of $10.93 and a 52 week high of $25.05. The company has a quick ratio of 23.99, a current ratio of 23.99 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $830.30 million, a P/E ratio of -2.89 and a beta of 1.03.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Wednesday, May 8th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.28. The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative return on equity of 92.04%. The firm’s revenue was down 26.5% on a year-over-year basis. During the same period in the prior year, the company earned ($1.61) earnings per share. Equities research analysts anticipate that Viridian Therapeutics, Inc. will post -3.61 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.